Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Tonix Pharm Holdings (TNXP)
Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,617
  • Shares Outstanding, K 26,762
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,220 K
  • 60-Month Beta 2.23
  • Price/Sales 0.92
  • Price/Cash Flow N/A
  • Price/Book 0.05
Trade TNXP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.26
  • Most Recent Earnings $-1.83 on 11/09/23
  • Latest Earnings Date 03/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.46
  • Number of Estimates 3
  • High Estimate -1.29
  • Low Estimate -1.64
  • Prior Year -3.50
  • Growth Rate Est. (year over year) +58.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2760 +16.67%
on 01/24/24
0.3900 -17.44%
on 02/20/24
+0.0301 (+10.31%)
since 01/23/24
3-Month
0.2600 +23.85%
on 01/19/24
0.6918 -53.45%
on 12/19/23
-0.1600 (-33.20%)
since 11/22/23
52-Week
0.2600 +23.85%
on 01/19/24
4.9369 -93.48%
on 03/03/23
-4.2474 (-92.95%)
since 02/23/23

Most Recent Stories

More News
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END

TNXP : 0.3220 (+1.77%)
PFE : 27.76 (+0.76%)
LLY : 769.54 (-0.01%)
ABBV : 178.09 (+0.76%)
MRK : 129.45 (+0.15%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

TNXP : 0.3220 (+1.77%)
PFE : 27.76 (+0.76%)
LLY : 769.54 (-0.01%)
ABBV : 178.09 (+0.76%)
MRK : 129.45 (+0.15%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease

A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical...

OPTI.CN : 0.3100 (+6.90%)
SEEL : 0.9950 (+20.17%)
NUMI.TO : 0.1100 (unch)
NUMIF : 0.0819 (+0.61%)
ATAI : 1.8300 (unch)
OPTHF : 0.2220 (-0.58%)
TNXP : 0.3220 (+1.77%)
TAK : 14.62 (-0.14%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...

SEEL : 0.9950 (+20.17%)
TAK : 14.62 (-0.14%)
ATAI : 1.8300 (unch)
TNXP : 0.3220 (+1.77%)
OPTI.CN : 0.3100 (+6.90%)
OPTHF : 0.2220 (-0.58%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease

/PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten...

OPTI.CN : 0.3100 (+6.90%)
OPTHF : 0.2220 (-0.58%)
SEEL : 0.9950 (+20.17%)
TAK : 14.62 (-0.14%)
ATAI : 1.8300 (unch)
TNXP : 0.3220 (+1.77%)
Psychedelics Use Among Young Adults Reaches All-Time High

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever.  According to a National Institute of Health...

OPTI.CN : 0.3100 (+6.90%)
OPTHF : 0.2220 (-0.58%)
SEEL : 0.9950 (+20.17%)
NUMI.TO : 0.1100 (unch)
NUMIF : 0.0819 (+0.61%)
ATAI : 1.8300 (unch)
TNXP : 0.3220 (+1.77%)
Psychedelics Use Among Young Adults Reaches All-Time High

/PRNewswire/ -- Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to...

OPTI.CN : 0.3100 (+6.90%)
NUMI.TO : 0.1100 (unch)
OPTHF : 0.2220 (-0.58%)
SEEL : 0.9950 (+20.17%)
NUMIF : 0.0819 (+0.61%)
ATAI : 1.8300 (unch)
TNXP : 0.3220 (+1.77%)
Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S....

TNXP : 0.3220 (+1.77%)
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain

New patent expected to expire in 2036 Phase 2 Study for Prevention of Migraine Headache Expected to Start Second Half 2022 CHATHAM, N.J., Aug. 01, 2022 ...

TNXP : 0.3220 (+1.77%)
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection

Phase 1 Clinical Study Expected to be Initiated in Kenya in the First Half of 2023 World Health Organization Has Declared Monkeypox a Global Health...

TNXP : 0.3220 (+1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 0.3513
2nd Resistance Point 0.3407
1st Resistance Point 0.3313
Last Price 0.3220
1st Support Level 0.3113
2nd Support Level 0.3007
3rd Support Level 0.2913

See More

52-Week High 4.9369
Fibonacci 61.8% 3.1503
Fibonacci 50% 2.5984
Fibonacci 38.2% 2.0466
Last Price 0.3220
52-Week Low 0.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar